Capricor trial investigators write to FDA urging approval of deramiocel; shares rise
Investigator lobbying ahead of a regulatory decision signals unusually high stakes for the Duchenne muscular dystrophy cell therapy.
Read at Stocktwits →Full coverage · 6 outlets
- Stocktwits · lead
- Yahoo FinanceCAPR Stock on Track For Worst Month Since July AdCom Vote On Deramiocel As November FDA Decision Nears
- scanx.tradeCapricor investors face Sept 28 deadline in deramiocel fraud suit
- MarketBeatCapricor Therapeutics (CAPR) Stock Price, News & Analysis
- Tech TimesFDA Panel Rejects Deramiocel Evidence as Lancet Validates Same Trial Data
- MSNCAPR stock rises as clinical trial investigators write to FDA urging approval for Deramiocel